within Pharmacolibrary.Drugs.N_NervousSystem.N04B_DopaminergicAgents.N04BA04_Melevodopa;

model Melevodopa
  extends Pharmacolibrary.Drugs.ATC.N.N04BA04;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>N04BA04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Melevodopa is a methyl ester prodrug of levodopa used for the treatment of Parkinson's disease. It is rapidly absorbed from the gastrointestinal tract and converted to levodopa, which is then decarboxylated to dopamine in the brain to replenish depleted dopamine stores. Melevodopa has been used as an alternative to levodopa to improve oral bioavailability and reduce response fluctuations. It is not widely used or approved in most countries today, as levodopa and its combinations remain the standard of care.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for oral administration of melevodopa in adult subjects, based on sparse literature about its rapid absorption and conversion to levodopa.</p><h4>References</h4><ol><li><p>Stocchi, F, &amp; Vacca, L (2019). A systematic review on the clinical experience with melevodopa/carbidopa fixed combination in patients with Parkinson disease. <i>Minerva medica</i> 110(6) 575–585. DOI:<a href=&quot;https://doi.org/10.23736/S0026-4806.19.06330-4&quot;>10.23736/S0026-4806.19.06330-4</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31965781/&quot;>https://pubmed.ncbi.nlm.nih.gov/31965781</a></p></li><li><p>Stocchi, F, &amp; Marconi, S (2010). Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio). <i>Clinical neuropharmacology</i> 33(4) 198–203. DOI:<a href=&quot;https://doi.org/10.1097/WNF.0b013e3181de8924&quot;>10.1097/WNF.0b013e3181de8924</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20414107/&quot;>https://pubmed.ncbi.nlm.nih.gov/20414107</a></p></li><li><p>Antonini, A, et al., &amp; Odin, P (2010). Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson&#x27;s disease. <i>CNS drugs</i> 24(2) 119–129. DOI:<a href=&quot;https://doi.org/10.2165/11310940-000000000-00000&quot;>10.2165/11310940-000000000-00000</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20088619/&quot;>https://pubmed.ncbi.nlm.nih.gov/20088619</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Melevodopa;
